

# DT Journal

12<sup>2021</sup>

**Journal of Diagnostics and  
Treatment of Oral and  
Maxillofacial Pathology**



Editors  
Oleksii Tymofieiev • Rui Fernandes  
(Kyiv, Ukraine • Jacksonville, FL, USA)



Official Journal of the  
Ukrainian Association for  
Maxillofacial and Oral Surgeons

[DTJournal.org](http://DTJournal.org)

# U-Impl<sup>®</sup>

SWITZERLAND



№ R3M 804 252 B2

Сертифікат відповідності  
технічного регламенту  
щодо медичних виробів



Switzerland Aarbergerstrasse 107A, CH-2502  
Biel, Phone/Fax +41 323230188  
info@u-impl.com  
www.u-impl.com

# About the Journal: Aims and Scope

DECEMBER 2021 • VOLUME 5 • ISSUE 12  
www.djournal.org

## Official Title

*Journal of Diagnostics and Treatment of Oral and Maxillofacial Pathology*

## Standard Abbreviation: ISO 4

*J. Diagn. Treat. Oral Maxillofac. Pathol.*

## Acronym

JDTOMP

## International Standard Serial Numbers (ISSNs)

Print ISSN 2519-2086 | Online ISSN 2522-1965

## Aims & Scope

This is a monthly peer-reviewed oral and maxillofacial surgery journal focused on: Microvascular and jaw reconstructive surgery, dental implants, salivary gland tumors/diseases, TMJ lesions, virtual surgical planning, implementation of ultrasonography into the practice of oral and maxillofacial surgeons.

## Editorial Board (EB) Composition

- EB shows significant geographic diversity representing 28 opinion leaders from 13 countries: Brazil, Canada, Colombia, Greece, Hong Kong (SAR, China), India, Israel, Italy, Slovak Republic, Spain, Ukraine, United Arab Emirates, and United States.
- The majority of the EB Members have a discernible publication history in Scopus, Web of Science, and journals with a high impact factor.
- The publication records of all EB members are consistent with the stated scope and published content of the journal.
- The journal has a several full-time professional editors.
- Gender distribution of the editors: 10.71% women, 89.28% men, 0% non-binary/other, and 0% prefer not to disclose.

## Frequency

12 print/online issues a year (from January 2020)

## Publication History

2017: 4 issues a year

2018: 4 issues a year

2019: 10 issues a year

From 2020: 12 issues a year

## Publishing Model

*Journal of Diagnostics and Treatment of Oral and Maxillofacial Pathology* is a fully open access and peer-reviewed publication.

## Type of Peer Review

The journal employs “double blind” reviewing.

## Article Publishing Charge (APC)

During hard times of Covid-19 pandemic our journal trying to support authors by reducing the APC by 50%. And by the end of December 2021 the APC will be 100 USD and 50 USD (excluding taxes) depending on the article's type. Details at website: [dtjournal.org](http://dtjournal.org).

## 13 Types of Articles Currently Published by the Journal

Editorials/Guest Editorials/Post Scriptum Editorials, Images, Case Reports/Case Series, Original Articles, Review Articles, Discussions, Paper Scans (*synonyms*: Review of Articles, Literature Scan), Book Scans (*synonym*: Book Reviews), Letters to the Editor (*synonym*: Letters), and Viewpoints.

## State Registration: Ministry of Justice of Ukraine

Registration: Jul 28, 2016 (Certificate: KB № 22251-12151 P)

Re-registration: May 21, 2019 (Certificate: KB № 23999-13839 IIP)

Re-registration: Aug 10, 2021 (Certificate: KB № 24951-14891 IIP)

## Co-Founders

1. Shupyk National Healthcare University of Ukraine (formerly known as Shupyk National Medical Academy of Postgraduate Education).
2. Private Higher Educational Establishment “Kyiv Medical University.”
3. OMF Publishing, Limited Liability Company.

## Publisher

OMF Publishing, LLC is an academic publisher focused on medical and linguistic sciences.

Address: 13-A Simferopolska Street, Office 121, Kyiv 02096, Ukraine.

## Crossref Membership

OMF Publishing, LLC is a member of Publishers International Linking Association, Inc. which doing business as a Crossref. OMF Publishing's active membership: From February 2017 to present.

## Official Journal of the Association

Ukrainian Association for Maxillofacial and Oral Surgeons

## Ukrainian Association for Maxillofacial and Oral Surgeons (UAMOS)

Address: 4-A Profesora Pidvysotskoho Street, Kyiv 01103, Ukraine.

Tel., fax: +38 044 528 35 17.

Website: [uamos.org](http://uamos.org).

## Subscription Index

In Ukraine: 60077 | In Donetsk/Luhansk Regions: 88263.

See page A5.

© 2021 OMF PUBLISHING, LLC

# Editorial Board

DECEMBER 2021 • VOLUME 5 • ISSUE 12  
www.djournal.org

## Editor in Chief

**Oleksii O. Tymofieiev, ScD**  
Kyiv, Ukraine

## Deputy Editor in Chief

**Rui P. Fernandes, MD, DMD, FACS, FRCS(Ed)**  
Jacksonville, Florida, United States

## Section Editors

### Bone Augmentation Techniques

**Nardy Casap, MD, DMD**  
Jerusalem, Israel

### Business

**Ivan V. Nagorniak, MSc, PhD**  
Kyiv, Ukraine

### Craniofacial Deformities

**Sunil Richardson, MDS**  
Nagercoil, Tamil Nadu, India

### Facial Feminization Surgery

**Kyle Keojampa, MD, FACS**  
Los Angeles, California, United States

### Facial Plastic Surgery

**Tirbod Fattahi, MD, DDS, FACS**  
Jacksonville, Florida, United States

### Head & Neck Oncologic Surgery

**Todd C. Hanna, MD, DDS, FACS**  
New York, New York, United States

### Head & Neck Radiology

**Anil T. Ahuja, MBBS, MD, FRCR, FHKCR, FHKAM**  
Hong Kong, SAR, China

### Images

**Camilo Mosquera, DDS**  
Bogotá, D.C., Colombia

### Orthognathic Surgery

**Mario Brinhole**  
São Paulo, São Paulo, Brazil

### Robotic Surgery

**Salam O. Salman, MD, DDS, FACS**  
Jacksonville, Florida, United States

### TMJ Lesions/Disorders

**Belmiro C. Vasconcelos, DDS, PhD**  
Recife, Pernambuco, Brazil

## Editorial Board Members

**Oleh M. Antonyshyn, MD, FRCS(C)**  
Toronto, Ontario, Canada

**Anthony M. Bunnell, MD, DMD, FACS**  
Jacksonville, Florida, United States

**Nur A. Hatab, DMD, PhD**  
Ras Al Khaimah, United Arab Emirates

**Andrey V. Kopchak, ScD**  
Kyiv, Ukraine

**Olindo Massarelli, MD, PhD, FEBOMFS**  
Sassari, Italy

**Anastasiya Quimby, DDS, MD**  
Fort Lauderdale, Florida, United States

**Daniel Robles Cantero, DDS, MSc**  
Madrid, Spain

**Peter Stanko, MD, PhD**  
Bratislava, Slovak Republic

**Rostyslav M. Stupnytskyi, ScD**  
Kyiv, Ukraine

**Olexander O. Tymofieiev, ScD**  
Kyiv, Ukraine

**Natalia O. Ushko, ScD**  
Kyiv, Ukraine

**Andrew Yampolsky, DDS, MD**  
Philadelphia, Pennsylvania, United States

## Web & Social Media Editor

**João L. Monteiro, DDS**  
Boston, Massachusetts, United States

## Director, Journal Development Department

**Evangelos G. Kilipiris, DMD**  
Thessaloniki, Greece | Bratislava, Slovak  
Republic

## Managing Editor

**Ievgen I. Fesenko, PhD**  
Kyiv, Ukraine



# TANTUM VERDE®

INFORMATION LEAFLET  
for the medicinal product

## **Composition:**

*active substance:* **benzydamine hydrochloride;**

100 mL of solution contain benzydamine hydrochloride 0.15 g;

*excipients:* ethanol 96%, glycerol, methyl parahydroxybenzoate (E 218), flavor (menthol), saccharin, sodium hydrocarbonate, Polysorbate 20, Quinoline Yellow (E 104), Patent Blue V (E 131), purified water.

**Dosage form.** Oromucosal solution.

*Basic physical and chemical properties:* a clear green liquid with a typical mint flavor.

**Pharmacotherapeutic group.** Dental preparations. Other agents for local oral treatment.

ATC code: A01A D02.

## **Pharmacological properties.**

### *Pharmacodynamics.*

Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antiexudative properties.

Clinical studies have shown that benzydamine is effective in the relief of symptoms accompanying localized irritation conditions of the oral cavity and pharynx. Moreover, benzydamine has anti-inflammatory and local analgesic properties, and also exerts a local anesthetic effect on the oral mucosa.

### *Pharmacokinetics.*

Absorption through the oral and pharyngeal mucosa has been proven by the presence of measurable quantities of benzydamine in human plasma. However, they are insufficient to produce any systemic pharmacological effect. The excretion occurs mainly in urine, mostly as inactive metabolites or conjugated compounds.

When applied locally, benzydamine has been shown to cumulate in inflamed tissues in an effective concentration

due to its ability to permeate through the mucous membrane.

## **Clinical particulars.**

### **Indications.**

Symptomatic treatment of oropharyngeal irritation and inflammation; to relieve pain caused by gingivitis, stomatitis, pharyngitis; in dentistry after tooth extraction or as a preventive measure.

### **Contraindications.**

Hypersensitivity to the active substance or to any other ingredients of the product.

### **Interaction with other medicinal products and other types of interaction.**

No drug interaction studies have been performed.

### **Warnings and precautions.**

If sensitivity develops with long-term use, the treatment should be discontinued and a doctor should be consulted to get appropriate treatment.

In some patients, buccal/pharyngeal ulceration may be caused by severe pathological processes. Therefore, the patients, whose symptoms worsen or do not improve within 3 days or who appear feverish or develop other symptoms, should seek advice of a physician or a dentist, as appropriate.

Benzydamine is not recommended for use in patients hypersensitive to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs).

The product can trigger bronchospasm in patients suffering from or with a history of asthma. Such patients should be warned of this.

For athletes: the use of medicinal products containing ethyl alcohol might result in positive antidoping tests considering the limits established by some sports federations.

#### *Use during pregnancy or breast-feeding*

No adequate data are currently available on the use of benzydamine in pregnant and breastfeeding women. Excretion of the product into breast milk has not been studied. The findings of animal studies are insufficient to make any conclusions about the effects of this product during pregnancy and lactation.

The potential risk for humans is unknown.

TANTUM VERDE should not be used during pregnancy or breast-feeding.

#### *Effects on reaction time when driving or using machines*

When used in recommended doses, the product does not produce any effect on the ability to drive and operate machinery.

#### **Method of administration and doses.**

Pour 15 mL of TANTUM VERDE solution from the bottle into the measuring cup and gargle with undiluted or diluted product (15 mL of the measured solution can be diluted with 15 mL of water). Gargle 2 or 3 times daily. Do not exceed the recommended dose.

#### *Children.*

The product should not be used in children under 12 years due to a possibility of ingestion of the solution when gargling.

#### **Overdosage.**

No overdose has been reported with benzydamine when used locally. However, it is known that benzydamine, when ingested in high doses (hundreds times higher than those possible with this dosage form), especially in children, can cause agitation, convulsions, tremor, nausea, increased sweating, ataxia, and vomiting. Such acute overdose requires immediate gastric lavage, treatment of fluid/salt imbalance, symptomatic treatment, and adequate hydration.

#### **Adverse reactions.**

Within each frequency group, the undesirable effects are presented in order of their decreasing seriousness.

Adverse reactions are classified according to their frequency: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $<1/10$ ); uncommon ( $\geq 1/1,000$  to  $<1/100$ ); rare ( $\geq 1/10,000$  to  $<1/1,000$ ); very rare ( $<1/10,000$ ); frequency unknown (cannot be estimated from the available data).

*Gastrointestinal disorders:* rare – burning mouth, dry mouth; *unknown* – oral hypesthesia, nausea, vomiting, tongue edema and discoloration, dysgeusia.

*Immune system disorders:* rare – hypersensitivity reaction, *unknown* – anaphylactic reaction.

*Respiratory, thoracic and mediastinal disorders:* very rare – laryngospasm; *unknown* – bronchospasm.

*Skin and subcutaneous tissue disorders:* uncommon – photosensitivity; very rare – angioedema; *unknown* – rash, pruritus, urticaria.

*Nervous system disorders:* *unknown* – dizziness, headache.

TANTUM VERDE contains methyl parahydroxybenzoate, which can cause allergic reactions (including delayed-type reactions).

**Shelf life.** 4 years.

#### **Storage conditions.**

Do not store above 25°C. Keep out of reach of children.

#### **Packaging.**

120 mL of solution in a bottle with a measuring cup; 1 bottle per cardboard box.

#### **Dispensing category.**

Over-the-counter medicinal product.

#### **Manufacturer.**

Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A., Italy.

Location of the manufacturer and its business address.  
Via Vecchia del Pinocchio, 22 – 60100 Ancona (AN), Italy.

#### **Date of the last revision of the text.**

September 26, 2018.

Information leaflet is

**APPROVED** by

Order of the

**Ministry of Health of Ukraine**

No. 636 dated 01.10.2015

**Registration Certificate**

No. UA/3920/01/01

# Our Supporters

DECEMBER 2021 • VOLUME 5 • ISSUE 12  
www.djournal.org



**FIGURE.** Evangelos G. Kilipiris, MD, DMD from the National Institute of Children’s Diseases and Faculty of Medicine at Comenius University, Bratislava, Slovak Republic. A kind support of Dr. Kilipiris during the 5 years at the position of Director, Journal Development Department helped our journal to move forward and to evolve. An honorary plaque was presented to him on behalf of the Chief Editor with words “To a Founding Director, Author of Multiple Articles and Reviews, Great Thanks and Appreciation.” Photo was taken on November 23, 2021.

# Content

of the Volume 5 • Issue 12 • December 2021

A1 **Publisher & Editorial Office Information**

A2 **Editorial Board**

A5 **Our Supporters**


A6 **Content, Courtesy, & Erratum**

## BUSINESS: EDITORIAL

135 **Including Shareholders to Your Private Practice in Oral Surgery and Dentistry: Ukrainian Laws**  
Ivan V. Nagorniak

## EDITORIAL

137 **Evolving: Becoming a Printable Digital-only Journal from January 2022**  
Oleksii O. Tymofieiev, Ievgen I. Fesenko, & Evangelos G. Kilipiris



## COURTESY

*Journal's* cover image (virtual surgical planning for a segmental mandibular reconstruction with fibula transplant) is courtesy of Rui P. Fernandes, MD, DMD, FACS, FRCS.

Image was taken from the article: Fernandes RP, Quimby A, Salman S. Comprehensive reconstruction of mandibular defects with free fibula flaps and endosseous implants. *J Diagn Treat Oral Maxillofac Pathol* 2017;1(1):6–10.

<https://doi.org/10.23999/j.dtomp.2017.1.1>





## BUSINESS: EDITORIAL

Ivan V. Nagorniak, MSc, PhD, *Section Editor*

# Including Shareholders to Your Private Practice in Oral Surgery and Dentistry: Ukrainian Laws

Ivan V. Nagorniak

Dental clinic/office launch and development is non-easy task, which require not only a lot of efforts but also some level of the investments, especially for the commercial real estate and expensive equipment. And very often the amount of finances which one person or family is bringing to business may not be sufficient. Including of shareholders can help to reach that goal. Including the partners (ie, co-founders or shareholders) to your private clinic/office in a legal form of Limited Liability Company (LLC) are possible upon two stages: (1) upon the business launch and (2) upon the business existence. The second variant is more complicated and has to be analyzed.

In general, the relationships between the participants (also known as *shareholders* or *co-founders*) of the LLC are regulated by two laws: (1) the Law of Ukraine of February 6, 2018 # 2275-VIII "On Limited and Additional Liability Companies"<sup>1</sup> and (2) the Law of Ukraine of May 15, 2003 # 755-IV "On State Registration of Legal Entities, Individual Entrepreneurs and Public Associations."<sup>2</sup>

The Law # 2275-VIII establishes the rules for

the sale of share in the *charter capital*<sup>3</sup> [synonyms: *authorized capital, share capital*] of LLC.<sup>4</sup> And the Law # 755-IV defines the registration methods of corporate rights alienation and the procedure for state registration of changes of the company's participants and/or their shares in the charter capital.<sup>4</sup>

According to the Law # 2275-VIII, there are three main rules (for the participants of the company) for the paid alienation of corporate rights<sup>4</sup>:

1. The participant of the company has a preemptive right to purchase a share of another participant, which is sold to a third party (Part 1, Article 20).<sup>1</sup> Interestingly, that according to Part 3, Article 21, the charter may establish that participants do not have a preemptive right.<sup>1</sup>
2. The participant of the LLC who seeks to sell his share to a third party must notify other shareholder of this company in writing form (Part 3, Article 20).<sup>1</sup>
3. The company's participant may sell her/his share in the charter capital of the LLC only if it is paid (Part 3, Article 21).<sup>1</sup>

MSc, PhD, Head Doctor, Private Entrepreneur Nagorniak I.V., Kyiv, Ukraine

Author's address: Private Practice (Certificate for management system according to ISO 9001:2015 – Private Entrepreneur Nagorniak I.V.), 6-G Andruschenka Street, Office 6, Kyiv 01135, Ukraine.  
E-mail: [ivan.nagorniak@gmail.com](mailto:ivan.nagorniak@gmail.com)

Please cite this article as: Nagorniak IV. Including shareholders to your private practice in oral surgery and dentistry: Ukrainian laws. J Diagn Treat Oral Maxillofac Pathol 2021;5(12):135–6.

Paper received 11 November 2021  
Accepted 11 November 2021  
Available online 31 December 2021

<https://doi.org/10.23999/j.dtmp.2021.12.1>

© 2021 OMF Publishing, LLC. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by-nc/4.0/>).

Ukrainian lawyers emphasize that the rules for purchasing and selling a share of the company's charter capital established by law are immutable and universal, and those described in the Charter or Corporate Agreement are somewhat unique, as they may contain special options and options that expand the basic rules (provided they are not contrary to the law).<sup>4</sup> It is important to know that additional rules or even reservations may be included in the company's Charter, amended or excluded only by a unanimous decision of the General Meeting of Participants of LLC, which was attended by all participants.<sup>4</sup>

Official documents which are necessary for purchasing and selling of a share (parts of share) are:

1. A share purchase and sale agreement (synonyms: *the agreement of assignment of corporate rights* and *the agreement of purchase and sale of corporate rights*).<sup>4-6</sup>
2. Act of acceptance-transfer of share on notarial forms.<sup>4</sup>
3. Registration Card on making changes to the information on the legal entity contained in the Unified State Register of Legal Entities and Individual Entrepreneurs.
4. Receipt of payment of administrative fee.<sup>4</sup>
5. Decisions of the general meeting on determining the size of shares and the composition of the founders (ie, shareholders).
6. Application for admission to LLC or application for withdrawal from LLC.

In sum, attraction of the investments from new

partners as potential shareholders, can bring to the private practice a new strong impulse for growth but must be performed paying high attention to the details and in a legally correct form.

## REFERENCES (6)

1. On limited and additional liability companies [Ukrainian] [document on the internet]; Oct 06, 2021 [cited 2021 Nov 25]. Available from: <https://zakon.rada.gov.ua/laws/show/2275-19#Text>
2. On state registration of legal entities, individual entrepreneurs and public associations [Ukrainian] [document on the internet]; Aug 14, 2021 [cited 2021 Sep 25]. Available from: <https://zakon.rada.gov.ua/laws/show/755-15#Text>
3. Shemeta T. Share in the charter capital of a limited liability company: concept, legal nature [Ukrainian]. *Entrepreneurship Economy Law* 2019;1:55–60.
4. Purchase and sale of corporate rights [Ukrainian] [document on the internet]; Nov 24, 2021 [cited 2021 Nov 25]. Available from: <https://www.expert-in.com.ua/kupivlya-prodazh-korporatyvnykh-prav/>
5. Document designer: a corporate rights (share in the charter capital of LLC) purchase and sale agreement [Ukrainian] [document on the internet]; Nov 24, 2021 [cited 2021 Nov 25]. Available from: <https://instaco.com.ua/create-document/dogovir-kupivli-prodazhu-korporativnih-prav-chastki-v-statutnomu-kapitali-tov>
6. Agreement of purchase and sale share (part of share) in charter capital [Ukrainian] [document on the internet]; Jan 22, 2020 [cited 2021 Nov 25]. Available from: <https://blank.dtkr.ua/blank/537>



## EDITORIAL

# Evolving: Becoming a Printable Digital-only Journal from January 2022

Oleksii O. Tymofieiev<sup>a</sup>, Ievgen I. Fesenko<sup>b,\*</sup>, & Evangelos G. Kilipiris<sup>c</sup>

*What's dangerous is not to evolve.*

—Jeff Bezos

Founder of Amazon

After almost 5 years of publishing (from February 2017) of the *Journal of Diagnostics and Treatment of Oral and Maxillofacial Pathology* (JDTOMP) in both forms (print and digital), we are happy to announce the paradigm shift in the life of our beloved publication. The Editorial Board made the decision to move the Journal to a digital-only publication format from January 2022.

In recent years, many prestigious international peer-reviewed journals with a long history of publishing and a strong Impact Factor already made or are ferociously making such transition to digital-only format (Table 1).<sup>1-4</sup>

Among many reasons of such transition are: (1) move to environmentally friendly format only,<sup>3</sup> (2) spared finances in printing, subscribing, and logistics can be invested into development of media platform and technologies on its basis,<sup>3</sup> (3) richer digital content, due to the fact that some journals do not print all pages in color,<sup>5</sup> (4) reader engagement with print text is difficult to measure,<sup>1</sup> (5) this

transition reflecting the reality of how readers are using journal content in the days of internet access,<sup>2</sup> (6) when preparing the draft of the manuscript an author rather uses internet search and downloads the multiple articles' PDF files, etc.

Such transition applies not only to medical journals. For example, such publisher as the American Institute of Aeronautics and Astronautics successfully moved all their eight journals to digital-only format in a 2017 to 2019 period.<sup>6</sup>

In our opinion, the popular term for the description of the electronic journal's format the "online-only publication" is a misnomer as it's not completely representing the potential of such publishing format of the journal. Because typically every article has a PDF file which can be printed at home, shop, or office. And in our Journal the website visitor can download both separate paper and a full issue. Thus, reader receives a possibility to work autonomously in case of loss/absence of internet connection. That is why our team proposes to use the term "printable digital journal."

And now, thanks to the team of OMF Publishing LLC our Journal has applied the evolving step similar to the journals of Oxford University Press,<sup>1,2,4</sup> John

<sup>a</sup> Editor in Chief, Kyiv, Ukraine.

<sup>b</sup> Managing Editor, Kyiv, Ukraine.

<sup>c</sup> Director, Journal Development Department, Bratislava, Slovak Republic.

\* Corresponding author's address: OMF Publishing LLC: Journal of Diagnostics and Treatment of Oral and Maxillofacial Pathology. 13-A Simferopolska Street, Kyiv 02096, Ukraine.  
E-mail: [i.i.fesenko@dtjournal.org](mailto:i.i.fesenko@dtjournal.org) (Ievgen Fesenko)

Please cite this article as: Tymofieiev OO, Fesenko II, Kilipiris EG. Evolving: becoming a printable digital-only journal from January 2022. *J Diagn Treat Oral Maxillofac Pathol* 2021;5(12):137–8.

Available online 31 December 2021

<https://doi.org/10.23999/j.dtmp.2021.12.2>

© 2021 OMF Publishing, LLC. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by-nc/4.0/>).

**TABLE 1.** Example of Peer-Reviewed Journals which Moved to Digital-only Format of Existence.<sup>1-4</sup>

#	Title	2020 Impact Factor	Number of Years of Print Format Publishing	Month and Year of Transition to Digital-only Format
1	Journal of Tropical Pediatrics	1.165	63	January 2018
2	Journal of the History of Medicine and Allied Sciences	2.088	74	July 2020
3	ANZ Journal of Surgery	1.872	90	January 2022
4	Age and Ageing	10.668	50	January 2022
5	Journal of Diagnostics and Treatment of Oral and Maxillofacial Pathology	-	5	January 2022

Wiley & Sons, Inc,<sup>3</sup> Elsevier,<sup>5</sup> and other publishers<sup>5</sup> to be “more agile”<sup>3</sup> and “to avoid becoming a fossil.”<sup>7</sup>

In sum, we hope you will enjoy the new chapter in the growth and evolution of our Journal in the form of a fully open access printable digital publication.

*Most readers already access the journal's content online.*<sup>3</sup>

—Julian A. Smith (2021)

Editor in Chief, *ANZ Journal of Surgery*

*Today you have that gift of a free distribution [via internet].*<sup>8</sup>

—Jeff Bezos (2018)

Founder of Amazon at the Economic Club of Washington, D.C. answering about buying Washington Post

### REFERENCES (8)

1. Bassat Q. Goodbye paper: we are moving to online only publication. *J Trop Pediatr* **2017**;63(6):417. <https://doi.org/10.1093/tropej/fmx076>
2. Hirshbein L. Editorial - news about the Journal of the History of Medicine and Allied Sciences. *J Hist Med Allied Sci* **2020**;75(3):243–4. <https://doi.org/10.1093/jhmas/jraa026>
3. Smith JA, Malisano LP. ANZ Journal of Surgery: soon to make the shift from print to digital publishing. *ANZ J Surg* **2021**;91(6):1051. <https://doi.org/10.1111/ans.16919>
4. Harwood RH. Editor's view. *Age Ageing* **2021**;50(6):1863–4. <https://doi.org/10.1093/ageing/afab202>
5. Wymbs S. To print or not to print — 4 things societies should consider before moving members online only [document on the internet]; 11 Nov **2020** [cited 25 Dec 2021]. Available from: <https://www.elsevier.com/connect/4-things-to-weigh-before-moving-a-journal-from-print-to-online-only>
6. Daily JW. Transition to online-only journals in 2019. *J Aircr* **2018**;55(5):1761. <https://doi.org/10.2514/1.C035178>
7. Goldsworthy S. The evolution of academic publishing in a digital age [document on the internet]; 06 Nov **2021** [cited 26 Dec 2021]. Available from: <https://www.universityworldnews.com/post.php?story=20211101135742731>
8. Jeff Bezos, CEO and Founder, Amazon [document on the internet]; 21 Sep **2018** [cited 26 Dec 2021]. Available from: <https://m.youtube.com/watch?v=zN1PyNwjHpc>

# TANTUM VERDE®

QUICK RELIEF FROM PAIN AND INFLAMMATION IN THE MOUTH AND THROAT<sup>1</sup>


**AN INTEGRAL COMPONENT OF THE TREATMENT OF PAIN AND INFLAMMATION IN THE ORAL CAVITY IN 60 COUNTRIES WORLDWIDE!<sup>2</sup>**



Reg. № UA/3920/01/01

**LOCAL ANESTHETIC AND ANTI-INFLAMMATORY EFFECT<sup>1</sup>**

- **JAWS FRACTURES<sup>3</sup>**
- **IMPLANTS PLACEMENT<sup>4</sup>**
- **WOUNDS OF ORAL CAVITY<sup>5</sup>**



#### SUMMARY OF PRODUCT CHARACTERISTICS

**NAME OF THE MEDICINAL PRODUCT.** Tantum Verde 0.15% mouthwash. **QUALITATIVE AND QUANTITATIVE COMPOSITION.** Each 100 ml contains: active ingredient: benzydamine hydrochloride 0.15 g (equivalent to 0.134 g of benzydamine). **Therapeutic indications.** Treatment of symptoms such as irritation/inflammation including those associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis and pharyngitis), including those resulting from conservative or extractive dental therapy. **Posology and method of administration.** Pour 15 ml of Tantum Verde mouthwash into the measuring cup, 2-3 times per day, using it either at full concentration or diluted. If diluted, add 15 ml of water to the graduated cup. Do not exceed the recommended dosage. **Contraindications.** Hypersensitivity to benzydamine or to any of the excipient. **PHARMACOLOGICAL PROPERTIES. Pharmacodynamic properties.** Pharmacotherapeutic group: Stomatologic drugs: other agents for local oral treatment, ATC code: A01AD02. Clinical studies demonstrate that benzydamine is effective in relieving suffering from localised irritation of the mouth and pharynx. In addition, benzydamine possesses a moderate local anaesthetic effect. **Pharmacokinetic properties. Absorption.** Absorption through the oropharyngeal mucosa is demonstrated by the presence of measurable quantities of benzydamine in human plasma. These levels are insufficient to produce systemic effects. **Distribution.** When applied locally, benzydamine has been shown to accumulate in inflamed tissues where it reaches effective concentrations because of its capacity to penetrate the epithelial lining.

**Information about medicines. Information for health care professionals for use in professional activities.**

1. Інструкція для медичного застосування лікарського засобу Тантум Верде®, розчин для ротової порожнини, РПН № UA/3920/01/01, затверджено Наказом Міністерства охорони здоров'я України № 636 від 01.10.2015.

2. <http://www.angelini-pharma.com/wps/wcm/connect/com/home/Angelini+Pharma+in+the+world/>

3. Тимофеев А.А. и др. "Особенности гигиены полости рта для профилактики воспалительных осложнений при переломах нижней челюсти". Современная стоматология 2015;1(75):52-8.

4, 4.5. Tymofiejew O.O. et al "Prevention of inflammatory complications upon surgeries in maxillofacial region". J Diagn Treat Oral Maxillofac Pathol. 2017;1:105-12.

Clinical and CT images are courtesy of: Ievgen Fesenko (Department of Oral & Maxillofacial Surgery, PHEI "Kyiv Medical University", Kyiv, Ukraine), Oleg Mastakov ("SCIEDECE—Scientific Center of Dentistry & Ultrasound Surgery" Kyiv, Ukraine)



04119, Kiev, Melnikova str. 83D, of. 404.  
Tel.: (044) 538-01-26  
Fax: (044) 538-01-27

